$CORT

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

Class action lawsuit filed against $COPT alleging executives misrepresented relacorilant clinical trial strength and FDA approval prospects, harming investors.

Rosen Law Firm notifies Corcept investors about securities lawsuit alleging misrepresentation of relacorilant clinical data and concealment of FDA concerns during October 2024-December 2025.

Rosen Law Firm filed securities class action against Concorde International Group ($CIGL) alleging fraudulent promotion schemes and insider share dumping. Affected investors must act before critical deadlines.

U.S. stocks fell to four-month lows as Brent crude hit $110 and rate-hike odds climbed, spurring stagflation concerns and precious metals selloff.

Class action lawsuit filed against $CORP alleging false statements about relacorilant clinical trial strength and FDA approval prospects. Investors from Oct 2024-Dec 2025 urged to participate.

Corcept Therapeutics faces class action lawsuit for allegedly misrepresenting FDA trial data; stock collapsed 50% after regulatory rejection of relacorilant drug.

FDA rejects Corcept's lead drug candidate, triggering 50% stock plunge and securities class action lawsuit. Lead plaintiff deadline set for April 21, 2026.

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant. Stock crashed 50% following misleading investor claims about approval prospects.

Rosen Law Firm seeks lead plaintiffs in securities class action against Corcept Therapeutics, alleging misrepresentation of FDA communications and clinical trial data for relacorilant drug.

Class action lawsuit filed against Corcept Therapeutics alleges material misstatements about relacorilant drug trials and regulatory approval prospects, covering investors from October 2024 through December 2025.

Class action lawsuit filed against $CORP alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects.

$CORT stock plummets 50% after FDA rejects lead drug relacorilant; class action targets alleged disclosure failures with lead plaintiff deadline April 21, 2026.

Rosen Law Firm sued Richtech Robotics for allegedly misrepresenting a Microsoft partnership. Investors must file claims by April 3, 2026.

Rosen Law Firm notifies $CORT investors of securities class action alleging misrepresentation of clinical trial data for relacorilant drug and undisclosed FDA concerns.

Rosen Law Firm files securities class action against Franklin BSP Realty Trust alleging false statements. Investors must act before lead plaintiff deadline.

Johnson Fistel investigates Corcept Therapeutics ($COPT) for securities violations after FDA rejected relacorilant application, triggering 50% stock decline.

Corcept Therapeutics faces securities class action over allegedly misleading statements about relacorilant's FDA approval prospects, triggering 50% stock plunge and $3.6B market cap loss.

Law firm Bragar Eagel & Squire files class action lawsuits against $NAVAN and $COPT alleging material misstatements, citing 60%+ and 50%+ stock declines respectively.

Schall Law Firm seeks investors in $COPT securities class action, alleging false statements about relacorilant FDA approval prospects between October 2024 and December 2025.